Zobrazeno 1 - 10
of 64
pro vyhledávání: '"Lisa M, Broad"'
Autor:
Karen J. Thompson, Sonia Watson, Chiara Zanato, Sergio Dall'Angelo, Joriene C. De Nooij, Bethany Pace‐Bonello, Fiona C. Shenton, Helen E. Sanger, Beverly A. Heinz, Lisa M. Broad, Noelle Grosjean, Jessica R. McQuillian, Marina Dubini, Susan Pyner, Iain Greig, Matteo Zanda, David Bleakman, Robert W. Banks, Guy S. Bewick
Publikováno v:
Experimental Physiology, Vol 109, Iss 1, Pp 81-99 (2024)
Abstract A metabotropic glutamate receptor coupled to phospholipase D (PLD‐mGluR) was discovered in the hippocampus over three decades ago. Its pharmacology and direct linkage to PLD activation are well established and indicate it is a highly atypi
Externí odkaz:
https://doaj.org/article/81a681306fa94df7a114941db1591a5b
Autor:
Andrew B. Tobin, Gerard R. Dawson, Patrick M. Sexton, Nathan Robertson, Sophie J. Bradley, Francesca Perini, Arthur Christopoulos, James C. Errey, Barry John Teobald, John Francis William Deakin, Lisa M. Broad, Jan Liptrot, Christopher J. Langmead, K.A. Bennett, Mary Vinson, Pradeep J. Nathan, Colin Molloy, Robert M. Cooke, Edward Hurrell, Michael Browning, Krzysztof Okrasa, Jason M Brown, Giulio Mattedi, Alastair J. H. Brown, David M. Cross, Greg J. Osborne, Julie E. Cansfield, Ali Jazayeri, Christoffer Bundgaard, Stephen R. Morairty, J.C. Patel, Fiona H. Marshall, Brian D. Hudson, Prakash Rucktooa, Robert T. Smith, Keith G. Phillips, Louis Dwomoh, Chris de Graaf, Malcolm Peter Weir, Julie Warneck, Giles A. Brown, Mark Pickworth, Benjamin G. Tehan, Tim Tasker, Anushka V. Goonawardena, Miles Congreve, João M. Dias, Shahram Shahabi
Current therapies for Alzheimer's disease seek to correct for defective cholinergic transmission by preventing the breakdown of acetylcholine through inhibition of acetylcholinesterase, these however have limited clinical efficacy. An alternative app
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b008b7a3c01abe25b8e63fdab465cc4
https://ora.ox.ac.uk/objects/uuid:fc10e298-8675-4411-9af5-3cfd801f0d78
https://ora.ox.ac.uk/objects/uuid:fc10e298-8675-4411-9af5-3cfd801f0d78
Autor:
Lisa M. Broad, Adrian J. Mogg, Elizabeth Eberle, Marcia Tolley, Dominic L. Li, Kelly L. Knopp
Publikováno v:
Pharmaceuticals, Vol 9, Iss 3, p 55 (2016)
Transient receptor potential vanilloid 3 (TRPV3) is a member of the TRP (Transient Receptor Potential) super-family. It is a relatively underexplored member of the thermo-TRP sub-family (Figure 1), however, genetic mutations and use of gene knock-out
Externí odkaz:
https://doaj.org/article/986bde7d689d45e6b4ea58786de7353f
Autor:
Alastair J H, Brown, Sophie J, Bradley, Fiona H, Marshall, Giles A, Brown, Kirstie A, Bennett, Jason, Brown, Julie E, Cansfield, David M, Cross, Chris, de Graaf, Brian D, Hudson, Louis, Dwomoh, João M, Dias, James C, Errey, Edward, Hurrell, Jan, Liptrot, Giulio, Mattedi, Colin, Molloy, Pradeep J, Nathan, Krzysztof, Okrasa, Greg, Osborne, Jayesh C, Patel, Mark, Pickworth, Nathan, Robertson, Shahram, Shahabi, Christoffer, Bundgaard, Keith, Phillips, Lisa M, Broad, Anushka V, Goonawardena, Stephen R, Morairty, Michael, Browning, Francesca, Perini, Gerard R, Dawson, John F W, Deakin, Robert T, Smith, Patrick M, Sexton, Julie, Warneck, Mary, Vinson, Tim, Tasker, Benjamin G, Tehan, Barry, Teobald, Arthur, Christopoulos, Christopher J, Langmead, Ali, Jazayeri, Robert M, Cooke, Prakash, Rucktooa, Miles S, Congreve, Malcolm, Weir, Andrew B, Tobin
Publikováno v:
Trends Pharmacol Sci
Current therapies for Alzheimer's disease seek to correct for defective cholinergic transmission by preventing the breakdown of acetylcholine through inhibition of acetylcholinesterase, these however have limited clinical efficacy. An alternative app
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::7763e10dd2dc92975133618856c2920a
https://pubmed.ncbi.nlm.nih.gov/35101279
https://pubmed.ncbi.nlm.nih.gov/35101279
Autor:
Mario Rossi, R. A. John Challiss, Colin Molloy, Eyassu Chernet, Sophie J. Bradley, Paulina Valuskova, Lisa M. Broad, Adrian J. Mogg, Karolina Gherbi, Vanessa N. Barth, Elizabeth M. Rosethorne, Andrew B. Tobin, Arthur Christopoulos, Caroline A. Wilson, Lisa Finlayson, Louis Dwomoh, Miriam Scarpa, Rajendra Mistry, Shuzo Sakata, Patrick M. Sexton, Kjell A. Svensson, David A. Sykes
Cholinesterase inhibitors, the current frontline symptomatic treatment for Alzheimer’s disease (AD), are associated with low efficacy and adverse effects. M1 muscarinic acetylcholine receptors (M1 mAChRs) represent a potential alternate therapeutic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e98a59cb796f11c7703f6b34d2e88b3
https://strathprints.strath.ac.uk/71527/1/Bradley_etal_NCB_2019_Biased_M1_muscarinic_receptor_mutant_mice_inform.pdf
https://strathprints.strath.ac.uk/71527/1/Bradley_etal_NCB_2019_Biased_M1_muscarinic_receptor_mutant_mice_inform.pdf
Autor:
Alastair J. H. Brown, Sophie J. Bradley, Giles A. Brown, Kirstie A. Bennett, Jason Brown, Julie E. Cansfield, David M. Cross, João M. Dias, James C. Errey, Edward Hurrell, Jan Liptrot, Colin Molloy, Pradeep J. Nathan, Krzysztof Okrasa, Greg Osbourne, Jayesh C. Patel, Mark Pickworth, Nathan Robertson, Shahram Shahabi, Christoffer Bundgaard, Keith Phillips, Lisa M. Broad, Anushka V. Goonawardena, Stephen R. Morairty, Michael Browning, Francesca Perini, Gerard R. Dawson, John F. W. Deakin, Robert T. Smith, Patrick M. Sexton, Julie Warneck, Mary Vinson, Tim Tasker, Benjamin G. Tehan, Barry Teobald, Arthur Christopoulos, Christopher J. Langmead, Ali Jazayeri, Robert M. Cooke, Fiona H. Marshall, Prakash Rucktooa, Miles S. Congreve, Malcolm Weir, Andrew Tobin
Publikováno v:
SSRN Electronic Journal.
Current therapies for improving memory in Alzheimer’s disease are focused on correcting for defective cholinergic transmission by increasing acetylcholine levels through inhibition of acetylcholinesterase enzymes. These treatments are however assoc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9223ad5ca22fdc8ece3f25838d310314
https://doi.org/10.2139/ssrn.3641933
https://doi.org/10.2139/ssrn.3641933
Autor:
Emanuele Sher, Adrian J. Mogg, Graham N. Wishart, Francesca Pasqui, David A. Evans, Christian C. Felder, Ellen M. Colvin, Ruud Zwart, Helen E. Sanger, Vanessa N. Barth, Lisa M. Broad, Paul Goldsmith
Publikováno v:
British Journal of Pharmacology. 176:110-126
Background and purpose We aimed to identify and develop novel, selective muscarinic M1 receptor agonists as potential therapeutic agents for the symptomatic treatment of Alzheimer's disease. Experimental approach We developed and utilized a novel M1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::91eb2fe354c4fd872c18a83d19d7a436
https://doi.org/10.1111/bph.14510
https://doi.org/10.1111/bph.14510
Autor:
Arthur Christopoulos, Colin Molloy, Michael D. Crabtree, Simon M. Brooke, Christoffer Bundgaard, Adrian J. Mogg, Patrick M. Sexton, Helen E. Sanger, Karen J. Thompson, Sophie J. Bradley, Christian C. Felder, Andrew B. Tobin, Christopher J. Langmead, Lisa M. Broad, Louis Dwomoh
Publikováno v:
Molecular Pharmacology. 93:645-656
The realization of the therapeutic potential of targeting the M1 muscarinic acetylcholine receptor (mAChR) for the treatment of cognitive decline in Alzheimer’s disease has prompted the discovery of M1 mAChR ligands showing efficacy in alleviating
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4e4008c1543e1e5e40a2a7a21ba0475a
https://doi.org/10.1124/mol.118.111872
https://doi.org/10.1124/mol.118.111872
Autor:
Frances Lu, Bryan G. Johnson, Daniel Ursu, Joan H. Carter, Lisa M. Broad, Kofi Adragni, Shane Atwell, Jing Wang, David K. Clawson, Beverly A. Heinz, Steven P. Swanson, James A. Monn, Qi Chen, Helene E. Sanger, David B. Shaw, Steven Marc Massey, Xushan Wang, Marijane Russell, Steven S. Henry, Junliang Hao, Rajni M. Bhardwaj, Diseroad Benjamin Alan, David L. McKinzie, Brian G. Getman, John T. Catlow
Publikováno v:
Journal of Medicinal Chemistry. 61:2303-2328
Multiple therapeutic opportunities have been suggested for compounds capable of selective activation of metabotropic glutamate 3 (mGlu3) receptors, but small molecule tools are lacking. As part of our ongoing efforts to identify potent, selective, an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::34fd3a986aac486e41e6ea738f1a4465
https://doi.org/10.1021/acs.jmedchem.7b01481
https://doi.org/10.1021/acs.jmedchem.7b01481
Autor:
Chuanxi Xiang, Steven Swanson, Joan H. Carter, Paul L. Ornstein, Lisa M. Broad, Charles H. Mitch, Xu Shan Wang, Wesley H. Anderson, Helen E. Sanger, Renhua Li, Jeffrey M. Witkin, Stephon C. Smith, Stephen M. Fitzjohn, Francesca Pasqui, Xia Li, Jodi L. Smith, James A. Monn, Beverly A. Heinz, John T. Catlow
Publikováno v:
Neuropharmacology. 115:100-114
Metabotropic glutamate 2/3 (mGlu2/3) receptors are of considerable interest owing to their role in modulating glutamate transmission via presynaptic, postsynaptic and glial mechanisms. As part of our ongoing efforts to identify novel ligands for thes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::52de977d52418e1e92a87b1acf0f81d6
https://doi.org/10.1016/j.neuropharm.2015.12.021
https://doi.org/10.1016/j.neuropharm.2015.12.021